BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
69.71
-4.81 (-6.45%)
At close: Apr 28, 2026, 4:00 PM EDT
70.25
+0.54 (0.77%)
After-hours: Apr 28, 2026, 5:13 PM EDT
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 24 analysts with 12-month price forecasts for BridgeBio Pharma stock have an average target of 86.04, with a low estimate of 49 and a high estimate of 125. The average target predicts an increase of 23.43% from the current stock price of 69.71.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock from 25 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 8 | 8 | 8 | 7 |
| Buy | 10 | 12 | 13 | 15 | 17 | 18 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 21 | 21 | 23 | 25 | 25 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Reiterates $106 | Buy | Reiterates | $106 | +52.06% | Apr 28, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +43.45% | Apr 27, 2026 |
| RBC Capital | RBC Capital | Buy Initiates $100 | Buy | Initiates | $100 | +43.45% | Apr 9, 2026 |
| Mizuho | Mizuho | Buy Maintains $91 → $106 | Buy | Maintains | $91 → $106 | +52.06% | Mar 18, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $89 → $94 | Buy | Maintains | $89 → $94 | +34.84% | Mar 10, 2026 |
Financial Forecast
Revenue This Year
951.20M
from 502.08M
Increased by 89.45%
Revenue Next Year
1.65B
from 951.20M
Increased by 73.78%
EPS This Year
-2.02
from -3.78
EPS Next Year
0.61
from -2.02
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.3B | 2.4B | ||||||
| Avg | 951.2M | 1.7B | ||||||
| Low | 771.1M | 1.1B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 159.1% | 151.4% | ||||||
| Avg | 89.5% | 73.8% | ||||||
| Low | 53.6% | 13.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.23 | 3.01 | ||||||
| Avg | -2.02 | 0.61 | ||||||
| Low | -3.20 | -1.53 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.